O	0	7	Results
O	8	12	from
O	13	14	a
O	15	25	randomized
O	26	31	trial
O	32	34	of
O	35	36	a
B-intervention	37	40	web
I-intervention	40	41	-
I-intervention	41	46	based
I-intervention	46	47	,
I-intervention	48	56	tailored
I-intervention	57	65	decision
I-intervention	66	69	aid
O	70	73	for
B-eligibility	74	79	women
I-eligibility	80	82	at
I-eligibility	83	87	high
I-eligibility	88	92	risk
I-eligibility	93	96	for
I-eligibility	97	103	breast
I-eligibility	104	110	cancer
O	110	111	.

O	112	114	To
O	115	121	assess
O	122	125	the
O	126	132	impact
O	133	135	of
O	136	141	Guide
O	142	144	to
O	145	151	Decide
O	152	153	(
O	153	156	GtD
O	156	157	)
O	157	158	,
O	159	160	a
O	161	164	web
O	164	165	-
O	165	170	based
O	170	171	,
O	172	182	personally
O	182	183	-
O	183	191	tailored
O	192	200	decision
O	201	204	aid
O	205	213	designed
O	214	216	to
O	217	223	inform
O	224	229	women
O	229	230	'
O	230	231	s
O	232	241	decisions
O	242	247	about
O	248	260	prophylactic
O	261	270	tamoxifen
O	271	274	and
O	275	285	raloxifene
O	286	289	use
O	289	290	.

O	291	305	Postmenopausal
O	306	311	women
O	311	312	,
B-age	313	316	age
I-age	317	319	46
I-age	319	320	-
I-age	320	322	74
O	322	323	,
B-eligibility	324	328	with
I-eligibility	329	334	BCRAT
I-eligibility	335	336	5
I-eligibility	336	337	-
I-eligibility	337	341	year
I-eligibility	342	346	risk
I-eligibility	347	348	â‰¥
I-eligibility	349	350	1
I-eligibility	350	351	.
I-eligibility	351	353	66
I-eligibility	353	354	%
I-eligibility	355	358	and
I-eligibility	359	361	no
I-eligibility	362	367	prior
I-eligibility	368	375	history
I-eligibility	376	378	of
I-eligibility	379	385	breast
I-eligibility	386	392	cancer
O	393	397	were
O	398	408	randomized
O	409	411	to
O	412	415	one
O	416	418	of
O	419	424	three
O	425	430	study
O	431	435	arms
O	435	436	:
O	436	448	intervention
O	449	450	(
O	450	451	n
O	451	452	=
B-intervention-participants	452	455	690
O	455	456	)
O	456	457	,
O	458	462	Time
O	463	464	1
O	465	472	control
O	473	474	(
O	474	475	n
O	475	476	=
B-intervention-participants	476	479	160
O	479	480	)
O	480	481	,
O	482	484	or
O	485	486	3
O	486	487	-
O	487	492	month
B-control	493	500	control
O	501	502	(
O	502	503	n
O	503	504	=
B-control-participants	504	507	162
O	507	508	)
O	508	509	.

O	510	522	Intervention
O	523	535	participants
O	536	542	viewed
O	543	546	GtD
O	547	552	prior
O	553	555	to
O	556	566	completing
O	567	568	a
O	569	573	post
O	573	574	-
O	574	578	test
O	579	582	and
O	583	584	3
O	585	590	month
O	591	597	follow
O	597	598	-
O	598	600	up
O	601	611	assessment
O	611	612	.

O	613	621	Controls
O	622	625	did
O	626	629	not
O	629	630	.

O	631	633	We
O	634	642	assessed
O	643	646	the
O	647	653	impact
O	654	656	of
O	657	660	GtD
O	661	663	on
O	664	669	women
O	669	670	'
O	670	671	s
O	672	682	decisional
O	683	691	conflict
O	692	698	levels
O	699	702	and
O	703	712	treatment
O	713	721	decision
O	722	730	behavior
O	731	733	at
O	734	738	post
O	738	739	-
O	739	743	test
O	744	747	and
O	748	750	at
O	751	752	3
O	753	759	months
O	759	760	,
O	761	773	respectively
O	773	774	.

O	775	787	Intervention
O	788	800	participants
O	801	804	had
O	805	818	significantly
O	819	824	lower
B-outcome	825	835	decisional
I-outcome	836	844	conflict
I-outcome	845	851	levels
O	852	854	at
O	855	859	post
O	859	860	-
O	860	864	test
O	865	866	(
O	866	867	p
O	867	868	<
O	868	869	0
O	869	870	.
O	870	873	001
O	873	874	)
O	875	878	and
O	879	892	significantly
O	893	899	higher
O	900	904	odds
O	905	907	of
O	908	914	making
O	915	916	a
O	917	925	decision
O	926	931	about
O	932	939	whether
O	940	942	or
O	943	946	not
O	947	949	to
O	950	954	take
O	955	967	prophylactic
O	968	977	tamoxifen
O	978	980	or
O	981	991	raloxifene
O	992	994	at
O	995	996	3
O	996	997	-
O	997	1002	month
O	1003	1009	follow
O	1009	1010	-
O	1010	1012	up
O	1013	1014	(
O	1014	1015	p
O	1015	1016	<
O	1016	1017	0
O	1017	1018	.
O	1018	1021	001
O	1021	1022	)
O	1023	1031	compared
O	1032	1034	to
O	1035	1042	control
O	1043	1055	participants
O	1055	1056	.

O	1057	1060	GtD
O	1061	1068	lowered
B-outcome	1069	1079	decisional
I-outcome	1080	1088	conflict
O	1089	1092	and
O	1093	1099	helped
O	1100	1105	women
O	1106	1108	at
O	1109	1113	high
O	1114	1118	risk
O	1119	1121	of
O	1122	1128	breast
O	1129	1135	cancer
O	1136	1142	decide
O	1143	1150	whether
O	1151	1153	to
O	1154	1158	take
O	1159	1171	prophylactic
O	1172	1181	tamoxifen
O	1182	1184	or
O	1185	1195	raloxifene
O	1196	1198	to
O	1199	1205	reduce
O	1206	1211	their
O	1212	1218	cancer
O	1219	1223	risk
O	1223	1224	.

O	1225	1228	Web
O	1228	1229	-
O	1229	1234	based
O	1234	1235	,
O	1236	1244	tailored
O	1245	1253	decision
O	1254	1258	aids
O	1259	1265	should
O	1266	1268	be
O	1269	1273	used
O	1274	1278	more
O	1279	1288	routinely
O	1289	1291	to
O	1292	1302	facilitate
O	1303	1311	informed
O	1312	1319	medical
O	1320	1329	decisions
O	1329	1330	,
O	1331	1337	reduce
O	1338	1346	patients
O	1346	1347	'
O	1348	1358	decisional
O	1359	1367	conflict
O	1367	1368	,
O	1369	1372	and
O	1373	1380	empower
O	1381	1389	patients
O	1390	1392	to
O	1393	1399	choose
O	1400	1403	the
O	1404	1413	treatment
O	1414	1422	strategy
O	1423	1427	that
O	1428	1432	best
O	1433	1441	reflects
O	1442	1447	their
O	1448	1451	own
O	1452	1458	values
O	1458	1459	.
